Renalytix’s De Novo Authorization For KidneyIntelX.dkd Paves Way To Other Markets, Channels

Renalytix president Tom Mclain outlined the company’s commercial strategy for its AI-powered blood test to detect early-stage kidney disease in patients with diabetes.